India, July 17 -- British drug major GSK plc (GSK,GSK.L) announced Thursday that the US Food and Drug Administration has approved a prefilled syringe presentation of Shingrix, GSK's Recombinant Zoster Vaccine or RZV, for the prevention of shingles or herpes zoster.
The company added that the prefilled syringe presentation of GSK's shingles vaccine is also undergoing regulatory review by the European Medicines Agency.
Consistent with the existing indications for Shingrix, the prefilled syringe presentation is licenced in the US for immunisation of adults aged 50 years and older, as well as those aged 18 years and older who are or will be at increased risk of shingles.
The US Centers for Disease Control and Prevention or CDC recommends two...